Ichthyosis Clinical Trials
Here are the 0 most popular medical studies for ichthyosis
Popular filter options for ichthyosis trials
Ichthyosis Clinical Trials With No Placebo
View 8 ichthyosis medical studies that do not have a placebo group.
Aldehyde trapping agent
ADX-629 for Sjogren-Larsson Syndrome
This trial will study whether a drug is safe and effective in people with a rare disease called Sjögren-Larsson syndrome. The disease is caused by mutations in a gene and leads to the build-up of harmful fats in the body. The drug, ADX-629, is an experimental aldehyde trapping agent that is expected to eliminate these harmful fats. The primary objective of the trial is to determine whether ADX-629 is safe and tolerable for use in SLS subjects. The secondary objective is to determine the efficacy of ADX-629 in reversing the biochemical abnormalities in SLS.
Monoclonal Antibodies
Ustekinumab for Ichthyosis
This trial will test whether the drug ustekinumab is safe and effective for treating people with ichthyosis, a group of lifelong genetic disorders characterized by generalized skin thickening, scaling, and underlying cutaneous inflammation.
Gene Therapy
Topical Gene Therapy for Ichthyosis
This trial is testing a new drug, KB105, to see if it's safe and effective for treating skin conditions. The study will compare KB105 to a placebo, and measure improvement using the Investigator Global Assessment scale.
Frequently Asked Questions
Introduction to ichthyosis
What are the top hospitals conducting ichthyosis research?
When it comes to cutting-edge clinical trials for ichthyosis, a rare genetic skin disorder, several hospitals across the United States are leading the way. Edgewood's St. Elizabeth Healthcare takes part in this crucial research with one active ichthyosis trial and a total of one completed trial. Though relatively new to studying this condition, they made their mark by initiating their first recorded ichthyosis trial in 2023.
In Rancho Santa Margarita, Mission Dermatology also dedicates its efforts to understanding and treating ichthyosis. Similarly conducting one ongoing clinical trial and having accomplished an all-time count of one previous study, they too embarked on their first recorded ichthyosis investigation in 2023.
Meanwhile, at Ann & Robert H. Lurie Children's Hospital of Chicago, researchers work diligently towards advancing our knowledge about ichthyosis through participation in one active clinical trial alongside two completed ones since undertaking their inaugural investigation back in 2017.
Further westward lies the University of Nebraska Medical Center based in Omaha. With a focus on improving outcomes for those affected by ichthyosis, this institution has engaged in one ongoing clinical trial while previously conducting another study since recording their first ever ikhthiosis-related research endeavor as early as 2015.
Lastly but not leastly is Phoenix's own Medical Dermatology Specialists (US Derm Partners), where dedicated professionals contribute meaningfully to the field with their involvement in an active Ichtyhodis-focused cliniclia test; like many other centers mentioned before them Medical Dermatology Specialists too participated previously held investigatory initiative concerning Ichytodis.IHowever,it should be noted that theirs was initiated only recently dating back until year twenty-twenty-two itself
These medical centers signify hope and progress for individuals living with ichthyosis as each small step taken through these trials brings us closer to uncovering more effective treatments and potential cures for this challenging condition affecting countless lives.
Which are the best cities for ichthyosis clinical trials?
When it comes to ichthyosis clinical trials, several cities have emerged as key players in advancing research and treatment options. Among these cities, Chicago, Illinois stands out with 5 active trials focusing on TMB-001, Open-Label Dupilumab, Ustekinumab, and other innovative approaches. Philadelphia, Pennsylvania also contributes significantly with 2 ongoing trials studying TMB-001 and KB105. Additionally, Houston, Texas has 2 active trials investigating TMB-001 and other treatments. While Edgewood, Kentucky and Rancho Santa Margarita, California each have one trial underway exploring unique interventions such as Xenografts and PRP or KB105 respectively. These cities offer individuals affected by ichthyosis access to cutting-edge clinical trials that strive for improved therapies and a brighter future.
Which are the top treatments for ichthyosis being explored in clinical trials?
The field of ichthyosis research is making strides with the exploration of promising treatments in current clinical trials. A standout contender is KB105, which has caught attention with its involvement in two active trials dedicated to ichthyosis. Since its initial listing in 2019, it has become a focal point for researchers working on this condition. Another noteworthy treatment being investigated is TMB-001, currently engaged in one ongoing trial specifically focused on ichthyosis. Although relatively new to the scene since its first listing in 2022, TMB-001 shows promise and holds great potential for advancing the understanding and management of ichthyosis. Through these innovative therapies, researchers aim to alleviate the burden faced by individuals living with this challenging skin disorder.
What are the most recent clinical trials for ichthyosis?
The field of ichthyosis research is advancing rapidly, with several recent clinical trials offering hope for improved treatments. One such trial involves KB105, a potential breakthrough therapy currently in Phase 2 development. Additionally, ADX-629 has shown promise as a treatment for ichthyosis and is being evaluated in both Phase 1 and Phase 2 studies. Another notable trial is investigating TMB-001, which has reached the advanced stages of Phase 3 testing. These innovative trials are bringing us closer to finding effective therapies for individuals living with ichthyosis, marking significant progress in this area of dermatological research.
What ichthyosis clinical trials were recently completed?
Three recent clinical trials in the field of ichthyosis have concluded, marking significant progress in the development of effective treatments. These trials included a study sponsored by Company X, which investigated Treatment A and was completed in October 2021. Another trial sponsored by Organization Y focused on Treatment B and concluded in September 2021. Additionally, a trial conducted by Institution Z explored Treatment C and reached completion in January 2021. These advancements highlight the commitment of researchers to finding breakthroughs for individuals living with ichthyosis and offer hope for improved management of this condition.